



# Research Tips

## University of Colorado Denver

Vice Chancellor for Research: RJ Traystman

07/01/2010

Volume 2 Issue 13

### Stimulus Funding Update (ARRA)

As of July 1, 2010, UCDenver has submitted 534 ARRA proposals and received ARRA funding for a total of 150 ARRA awards funded at \$62,538,956

### Office of Grants and Contracts (OGC)

#### InfoEd Proposal Development

During the past few months, OGC and University Information Systems (UIS) have been working together to implement the second phase of the InfoEd Grant Application called Proposal Development. This module, which is referred to as PD, provides the Principal Investigator/Administrator with the capability to develop electronic proposal applications within InfoEd, route them to OGC via the application in real-time and for OGC to submit the proposal to Grants.gov via direct connection to Grants.gov. PD provides all Grants.gov forms online and prompts the PI through the documentation required for the proposal submission. PD will not allow an incomplete proposal to move forward to routing and many of the forms will be pre-populated with commonly required institutional information.

The application has been tested extensively and we will be submitting two test proposals during June 2010. We plan to commence training and assigning PIs/Administrators to the InfoEd System in late summer 2010 after the test proposals have been submitted and evaluated. The initial proposal types that will be supported by PD include proposals for R03 and R21 program announcements. Schools and Colleges will be contacted to establish training schedules. OGC extends a warm thank you to faculty and administrators who have contributed their time and wisdom to this important system implementation. We are looking forward to InfoEd providing more efficient support to the research faculty and staff in proposal development and submission.

### Office of Laboratory Animal Medicine (OLAR)

#### OLAR Publishes Rates for the 2010/2011 Fiscal Year

OLAR has posted the new per diem and technical service rates for the 2010/2011 budget year on our website. Please see <http://www.ucdenver.edu/academics/research/AboutUs/animal/OLAR/Pages/BillingRates.aspx> (please cut/paste into your browser window). We were able to cap most of the rate increases to 7%. This is better than the 8% prediction that was sent out in the fall. As soon as possible, we will provide an updated 5 year outlook for grant planning purposes. If you have any questions contact Jori Leszczynski (303-724-3987).

### Dr. T's Corner

The thoroughbred horse owners now have a new tool to predict how their horses will perform at the race track. In January at the Irish Thoroughbred Breeders Association Expo, a new company called Equinome rolled out a €1000 DNA test of a muscle factor derived from the Horse Genome Project. Muscle growth is governed by myostatin, a protein that determines whether an animal has compact muscles tuned for rapid sprints or a leaner body designed for endurance. The company co-founder, a genetics researcher at University College in Dublin, and her colleagues reported that horses with two copies of the myostatin-suppressing C variant of the gene were more likely to win short races up to 6.5 furlongs (1.3 kilometers), whereas horses with two T variants did better in races up to 13.5 furlongs. Ernest Bailey of the University of Kentucky, Horse Genome Project Coordinator, indicates that breeders have adopted genetic tests for paternity, coat color, and diseases, but that performance prediction is novel. Horse gene researchers also indicate that they are investigating gene associations with other parameters such as aerobic capacity. This could give new meaning to the concept of conflict of interest.



### Colorado Multiple Institution Review Board (COMIRB)

#### InfoEd 2010 Conflict Of Interest Disclosure Submission Training

The Office of Regulatory Compliance will be holding step-by-step, hands-on training classes for submitting the 2010 COI Disclosure form. The following is the class schedule. Please note that all classes are limited to 20 participants.

**LOCATION:** ED2North P28 - CTI-2201DE - Computer Lab

#### **DATES & TIMES:**

Tuesday, July 6, 2010	9:00 - 11:00 a.m.
Thursday, July 8, 2010	1:00 - 3:00 p.m.
Tuesday, July 13, 2010	1:00 - 3:00 p.m.
Wednesday, July 21, 2010	1:00 - 3:00 p.m.
Friday, July 23, 2010	9:00 - 11:00 a.m.
Tuesday, July 27, 2010	1:00 - 3:00 p.m.
Thursday, July 29, 2010	9:00 - 11:00 a.m.
Tuesday, August 3, 2010	9:00 - 11:00 a.m.
Thursday, August 5, 2010	1:00 - 3:00 p.m.
Tuesday, August 10, 2010	1:00 - 3:00 p.m.
Thursday, August 12, 2010	9:00 - 11:00 a.m.
Wednesday, August 18, 2010	1:00 - 3:00 p.m.
Friday, August 20, 2010	9:00 - 11:00 a.m.

**RSVP:** Send your date preference to [Jennifer.a.lahlou@ucdenver.edu](mailto:Jennifer.a.lahlou@ucdenver.edu). You will receive a confirmation email.

**REMINDER:** COI Disclosures are due by September 3, 2010.

## Research Corner

Dr. David Ross is Chair of the Department of Pharmaceutical Sciences and Professor of Toxicology at the UC Denver School of Pharmacy. Dr. Ross received his BSc degree from the University of Aston in Birmingham, England. He received his PhD from that same institution and was a postdoctoral fellow at the Karolinska Institute in Stockholm and at the University of California Berkeley, before moving to Colorado.



*David Ross, PhD*

The State of Colorado and the University of Colorado Technology Transfer Office (TTO) fund the Bioscience, Discovery and Evaluation Grant (BDEG) Program. This program is designed to forward research and development of technologies that have been created in the University of Colorado system and where the university holds intellectual property rights. A recent BDEG award to the laboratory of Dr. Ross was entitled "Novel benzoquinone ansamycins. Hsp90 inhibitors with decreased toxicity." Hsp90 inhibitors are a relatively new class of anticancer agents. Hsp90 is a protein chaperone which assists the folding of other client proteins into their functional forms. Included in the list of clients that Hsp90 folds are multiple oncogenic proteins which drive different pathways leading to cancer. Inhibiting Hsp90 therefore allows a combinatorial inhibition of multiple pathways that drive neoplasia and consequently, Hsp90 has become an attractive anticancer target. The Hsp90 inhibitors that have progressed furthest into phase II clinical trials are benzoquinone ansamycins and Dr. Ross' group showed previously that the active Hsp90 inhibitor was not the parent benzoquinone ansamycin but a hydroquinone metabolite. This finding was initially controversial but is now well recognized and has led to new pro-drug targeting strategies. The major problematic issue with the benzoquinone ansamycins is their dose-limiting toxicity which often exhibits as liver toxicity. The current project explores a novel approach to mitigating the toxicity of the benzoquinone ansamycins focusing on minimizing both the generation of reactive oxygen species and reactive electrophilic metabolites derived from these molecules. A collaborating chemist, Dr. Christopher Moody from the University of Nottingham, UK will synthesize these molecules and Dr. Ross' laboratory will evaluate their Hsp90 inhibitory activity, antitumor activity and toxicity. The design of less toxic Hsp90 inhibitors will be a valuable step forward and these novel molecules will be favorably positioned for future preclinical and clinical development.

## Grant Information for Individuals with ARRA Awards

### When must ARRA projects be completed?

All ARRA funds must be obligated by NIH no later than September 30, 2010. In general, this will mean ARRA project period end dates will be no later than September 29, 2011. However, all ARRA awards are subject to the standard terms of award as indicated in the NIH Grants Policy Statement, including the authority to extend the final budget period of a previously approved project for up to 12 months without additional funds.

### Are no-cost extensions permissible for Challenge Grants?

The proposed award period in the Challenge Grant application will end on or before September 29, 2011. There are no specific constraints on no-cost extensions for the Challenge award program. All ARRA awards are subject to the standard terms of award as indicated in the NIH Grants Policy Statement including the authority to extend the final budget period of a previously approved project period for up to 12 months without additional funds. See: [http://grants.nih.gov/grants/policy/nihgps\\_2003/index.htm](http://grants.nih.gov/grants/policy/nihgps_2003/index.htm)

## Office of Laboratory Animal Medicine (OLAR)

### June 30 DEADLINE REMINDERS

#### We have two June 30 deadlines coming up

1. All investigators using DEA Controlled Substances in their laboratories are required to have their own DEA Registrations by June 30, 2010. OLAR will no longer be allowed to sell controlled substances to established laboratories after this date.
2. All claims for damaged or missing equipment as a result of the decontamination must be submitted to Jori Leszczynski ([jori.leszczynski@ucdenver.edu](mailto:jori.leszczynski@ucdenver.edu)) and Jan Collins ([Jan.Collins@ucdenver.edu](mailto:Jan.Collins@ucdenver.edu)) no later than June 30, 2010. Information needed is the equipment that was damaged or missing, the description of what the problem was, and an invoice or quote for the repair or replacement cost. Please note that it is unclear how long the process will take so it is recommended that you purchase or repair the item so that work can continue while everything is sorted out.

## Environmental Health Sciences

It is the policy of UC Denver, to transport all hazardous materials in secondary containment and use restricted paths of transport at the Anschutz Medical Campus. Hazardous chemicals, radioisotopes, infectious materials, animals, biological samples, or other hazardous/potentially hazardous materials transported within and between public spaces of research buildings are required to have secondary containment and use restricted paths of transport. The Anschutz Campus buildings are equipped with passenger and freight elevators. Passenger elevators should never be used to transport hazardous materials. When freight elevators are operational, these should always be the mode of transport between floors for potentially hazardous materials. Gloves should not be worn in the elevators or in any public areas as any transported materials must be in uncontaminated secondary containment-eliminating the need for gloves and possible contamination of elevator surfaces, door handles, etc. Always remove gloves and wash hands before leaving the laboratory. For questions or additional information please contact Justin Sterger at 303-724-2271 or [Justin.Sterger@ucdenver.edu](mailto:Justin.Sterger@ucdenver.edu).